
Should the GMC Regulate Doctors on Social Media?
Dr Arya Anthony Kamyab
Doctors have always held strong opinions, but where these were once exchanged in the privacy of hospital corridors, they are now broadcast globally via posts on social media platforms.
In January 2024, the General Medical Council (GMC) issued updated guidance titled "Using Social Media as a Medical Professional." This document underscores the importance of maintaining professionalism, upholding patient trust, and establishing clear boundaries online. Among its central tenets is this recommendation: 'You must not use social media to abuse, discriminate against, bully, harass or deliberately target any individual or group.'
Implementing this principle raises difficult questions. Where is the line between legitimate critique and perceived harassment? Is a doctor who publicly challenges unsafe working conditions within the NHS engaging in necessary advocacy or crossing a line by targeting leadership? Are discussions about the role of physician associates constructive criticism or professional bullying? The GMC offers little definitional clarity, placing doctors in ethically ambiguous territory.
In practice, social media has become an increasingly fraught space for healthcare professionals. Platforms such as X are rife with disputes — among colleagues, with administrators, and increasingly directed at the GMC itself. The ongoing debate around physician associates has inflamed tensions further, with allegations ranging from misinformation and professional gatekeeping to outright bullying. While the GMC has acknowledged the increasingly toxic tone of online discourse, its response has largely been limited to expressions of concern rather than decisive action.
This leads to a broader, more contentious question: Should the GMC be responsible for regulating physicians' conduct on social media at all? Some argue that professionalism is not confined to clinical settings and that behaviour inconsistent with medical ethics, regardless of context, undermines public trust. Others view such oversight as overreach, contending that physicians retain the right to express personal views outside of work.
The GMC now finds itself in a delicate position. Excessive enforcement risks accusations of censorship and the stifling of free expression; insufficient enforcement, however, may undermine its authority as a regulator. The power of professional regulation extends beyond legal authority — it includes reputational impact. A doctor facing a tribunal over an online post may endure not only formal investigation but also public scrutiny and reputational damage.
Free to Misinform?
It is tempting to view this free speech debate from a legalistic standpoint: Free speech is a right, and any interference is therefore a violation. But this simplifies what is a very complex moral discussion. Doctors occupy a very privileged epistemic position. Our speech is not just personal expression; it carries what can be referred to as epistemic weight. When doctors speak, people listen, and they often shape their actions in response. This could be dismissed as their responsibility, but to say so is to be naive about the forces that influence human behaviour.
During the COVID-19 pandemic, doctors who spread misinformation didn't just express unpopular views; they misled millions precisely because they were trusted by the public. Any ethical analysis must therefore conclude that doctors, by virtue of their training and the trust they hold, bear a higher moral burden. Their views must meet a threshold of intellectual honesty and evidential rigour. Has it therefore ever been more important for doctors to understand the hierarchy of evidence and the scientific method as a route to knowledge?
The Value of Dissent
We must resist the impulse to reduce all nonconforming speech to danger, however. Recognising that not all nonconforming speech is equal is also vital. There is a long tradition of those who challenged prevailing consensus and were vindicated over time: Ignaz Semmelweis, a pioneer of antiseptics; and Gregor Mendel, with his groundbreaking studies on inheritance, to name just two. But what separates such figures from conspiracists and pseudo-intellectuals is not what they challenged but how they did it. If one engages critically with the evidence, welcomes scrutiny, and embraces the methodology of the scientific process, then dissenting speech becomes not only valid but vital.
Therefore, if the GMC wishes to guide online professionalism without veering towards censorship, it must distinguish between these types of speech. However, the danger is that even the most well-intentioned guidance can become irrelevant in the context of social media. Social media is not a neutral forum. Its algorithms do not select for truth. Rather, it is an attention economy optimised for outrage, tribalism, and performance.
Platforms such as X reward impulsiveness and reactivity over reflection and deliberation. If social media's algorithms are designed to fuel hyperbole and outrage, can professionalism be meaningfully maintained within this space?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
an hour ago
- Forbes
Working With A Bootstrapped Healthcare Marketing Agency: What To Know
Ajay Prasad is the CEO of GMR Web Team, a full-service healthcare digital marketing agency focused on patient acquisition and retention. A strong digital presence is now essential for all healthcare practices aiming to thrive and connect with patients. When seeking a marketing partner, you'll encounter both large agencies with external funding partners as well as smaller bootstrapped agencies. You may have questions about the resources and reliability of bootstrapped firms compared to larger organizations with more monetary resources. Let's explore the value a bootstrapped agency can offer your practice and what you should consider if you choose to work with one. At its core, a bootstrapped healthcare digital agency is one that has grown and sustained itself primarily through its own revenue generation, without relying on significant external investment like venture capital. This often translates to a few key characteristics: • Resourcefulness and efficiency: Bootstrapped agencies tend to thrive on smart resource allocation and lean operations. They understand the value of every dollar and often prioritize delivering maximum impact with focused strategies. • Client-centric focus: Sustainable growth for a bootstrapped agency hinges on client satisfaction and long-term relationships. This often fosters a deep commitment to understanding and achieving your practice's specific goals. • Potential for specialization: Many bootstrapped agencies carve out a niche and develop deep expertise in specific areas of healthcare marketing, such as SEO for local patient acquisition, social media engagement for building community trust or content marketing tailored to patient education. • Direct leadership involvement: You'll often find that the founders and senior team members are directly involved in client strategy and execution at bootstrapped agencies, providing a level of personalized attention that can be less common in larger, more hierarchical organizations. • Expertise rooted in experience: The founders and teams at bootstrapped agencies often bring years of valuable experience in healthcare marketing. They may have intentionally chosen a self-funded path to maintain control over their vision and focus on delivering specialized expertise without the pressures of external investors. • Agility in a rapidly evolving digital landscape: The digital marketing world is constantly changing. Bootstrapped agencies, often with flatter structures and less bureaucratic processes, can be more nimble in adapting to new algorithm updates, emerging platforms and evolving patient behaviors. Ultimately, the success of your marketing partnership hinges on the agency's ability to understand your goals, develop effective strategies, execute them flawlessly and deliver measurable results. Whether an agency is funded by investors or its own revenue stream is less important than its expertise, its understanding of the healthcare market and its commitment to your success. If you're thinking about working with a bootstrapped agency, look for these crucial skills and offerings: Look for an agency that demonstrates a genuine understanding of the healthcare industry, including compliance regulations (like the Health Insurance Portability and Accountability Act), patient privacy concerns and the unique patient journey within your area of care. Request detailed case studies and speak to current or former clients (when possible and respecting privacy) to gauge the agency's experience and its ability to deliver tangible results for similar healthcare practices. Ensure the agency has clear communication processes, provides regular and transparent reporting on key performance indicators, and fosters collaborative partnerships. Inquire about the agency's approach to staying up to date on the latest digital marketing trends and its ability to adapt strategies based on performance data and evolving market conditions. Choose an agency whose values, communication style and overall approach resonate with your practice's culture. A strong partnership built on mutual understanding and trust is crucial for long-term success. Focus on the overall value proposition an agency offers—its expertise, personalized attention and potential return on investment—rather than just the cost of services. A bootstrapped agency might offer competitive pricing due to lower overhead, but ensure its expertise aligns with your needs. Partnering with a bootstrapped digital marketing agency can be a strategic move for your healthcare practice. But don't let the funding model be the sole determinant. Instead, prioritize a thorough evaluation of the agency's healthcare knowledge, track record, communication style and overall value proposition to find the right fit for your practice's unique needs and aspirations. Forbes Agency Council is an invitation-only community for executives in successful public relations, media strategy, creative and advertising agencies. Do I qualify?


Associated Press
an hour ago
- Associated Press
Gradient Denervation Technologies Announces Acceptance into FDA's Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its novel technology intended to treat patients with pulmonary hypertension and associated heart failure. The TAP Pilot acceptance follows the Company's recent announcement that the FDA granted Breakthrough Device Designation for the Gradient Denervation System. The FDA's Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite patient access to safe and effective, innovative medical devices. To help accelerate development of Gradient's Denervation System, the TAP Pilot will allow the company to have early and frequent interactions with FDA as well as obtain strategic advice from providers, associations, payors and patient organizations. The Gradient Denervation System is a novel technology intended to treat patients with Group 2 pulmonary hypertension due to left-sided heart disease. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. 'We're excited to be included in the TAP Pilot as the program will help streamline collaboration with FDA – from initiating our pivotal clinical study to accelerating access to this breakthrough therapy upon approval,' said Martin Grasse, Chief Executive Officer at Gradient Denervation Technologies. 'There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients, which reinforces the need to expedite access to new innovative therapies. We expect that guidance from TAP Pilot advisors will be immensely valuable in developing a targeted therapy intended to improve outcomes and quality of life for these underserved patients.' About Gradient Denervation Technologies Gradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use. For more information, please visit: Media Contact [email protected]

Associated Press
an hour ago
- Associated Press
Social and Economic Factors Explain Why Black Patients Lose Less Weight After Bariatric Surgery than Other Groups
NEW YORK, June 18, 2025 /PRNewswire/ -- Weight loss surgery has long been an effective treatment for the more than 40 percent of the American adults struggling with obesity. While previous studies show that Black patients lose less weight overall following bariatric surgery compared to other racial groups, less attention has been paid to the relationships between economic and social factors that may help explain differences in weight loss. New research led by NYU Langone Grossman School of Medicine found that Black patients who underwent sleeve gastrectomy, the most common weight loss surgery, between 2017 and 2020 lost 6.2 percent less weight than their White counterparts, and 4.9 percent less than Hispanic patients, after one year. However, further analyses found that a lot more complexity and interplay between non-biological factors than previously known appear to impact weight loss surgery incomes. Published online in the journal Obesity, this is the first study to investigate the relationship between a variety of economic and social factors that include income, sleep disturbances and stress, and weight loss differences among racial groups, the study authors said. 'Our findings identified variations in bariatric surgery outcomes so that we can address them and, when appropriate, offer patients individualized support that can help promote the best possible outcomes,' said Melanie Jay, MD, professor in the Departments of Medicine and Population Health at NYU Langone Health, and senior author of the study. How the Study was Conducted Study participants who self-identified as either Non-Hispanic Black, Hispanic, or Non-Hispanic White were recruited from NYU Langone Health Tisch Hospital and NYC Health + Hospital Bellevue Hospital from June 2017 to March 2020. The researchers measured patients' total weight loss, waist circumference, body composition, hormones, and blood glucose levels—following up with them at multiple intervals through in-clinic visits and questionnaires over two years. Analyzing data from 297 patients, the investigators found that after surgery, non-Hispanic Black patients lost less total weight at nearly every follow-up interval compared to their Hispanic and White counterparts. Black patients also consistently reported higher sleep disturbance, perceived stress, and experiences of discrimination. In contrast, no significant differences in total weight loss were observed between Hispanic and White patients. White patients also were found to have better long-term blood glucose control than both Black and Hispanic patients after follow-up. 'These varied associations highlight how different lived experiences and self-perceptions across racial and ethnic groups can influence surgical outcomes,' said Sally M. Vanegas, PhD, research assistant professor in the Department of Medicine and lead study author. 'Additional research is needed to better understand how a broader range of socioeconomic factors may shape these outcomes.' José O. Alemán, MD, PhD, an endocrinologist at NYU Langone and co-senior author of the study said he and his colleagues will continue analyzing data from the study participants to explore additional biological factors that may influence weight loss surgery outcomes, including changes in gene expression and the microbiome. 'As a clinical community, we have to be honest that these differences exist, as well as reinforce the importance of adopting a holistic approach to care.' In addition to Jay, Alemán and Vanegas, additional collaborators from NYU Langone Health include Silvia Curado, PhD, Boyan Zhou, PhD, Ericka N. Merriwether, PhD, Nicholas Illenberger, PhD, Evelyn Armijos, Ann Marie Schmidt, MD, Christine Ren-Fielding, Manish Parikh, MD, and Brian Elbel, PhD. The study was provided with institutional support from NYU Langone Health and obtained donor support through the J. Ira and Nicki Harris Family Foundation, an AHA Ignition Center Grant (17SFRN33590133), and the Clinical and Translational Science Institute (CTSI), which is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001445. SMV was in part supported by 2T32HL098129 from the National Heart, Lung and Blood Institute. JOA was in part supported by K08DK117064 from the National Institute of Diabetes and Digestive and Kidney Diseases and the Doris Duke Foundation. MJ was in part supported by the National Heart, Lung and Blood Institute (K24 HL165161-01A1). About NYU Langone Health NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise. Media Inquiries: Sasha Walek 646-501-3873 [email protected] View original content to download multimedia: SOURCE NYU Langone Health System